Phaseline

Companies › MediWound

MediWound: clinical trials, targets and expected readouts

2 active drug programs in 2 registered trials: 1 Phase 1, 1 Phase 3; Oncology, Cardiovascular; next expected readout Dec 2026.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
EscharEx (EX-03)
Proteolytic enzyme concentrate enriched in bromelain
–Phase 3Venous Leg Ulcer (VLU)Dec 2026
EscharEx (EX-02)
Proteolytic enzyme preparation (contains bromelain and papain)
–Phase 1Superficial Basal Cell Carcinoma–

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT05157763EscharEx (EX-02)Phase 1Superficial Basal Cell CarcinomaOncologyMay 2022
NCT06568627EscharEx (EX-03)Phase 3Venous Leg Ulcer (VLU)CardiovascularDec 2026

From the company's SEC filings

Cash of $5m on 2025-12-31; operating cash outflow about $16m a year; runway about 4 months at that burn, to Apr 2026; 0 of 1 coming phase 2-3 readouts fall inside that runway

Complete response letters from FDA

Specialist investors

Held by 1 of the 39 life-science funds Phaseline follows through their 13F filings. Who holds what.

Targets

No annotated target.

Companies with the same targets

–

Companies built like this

Relay Therapeutics Aura Biosciences Salubris Biotherapeutics Immuneering UroGen Pharma

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.